All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
This ASCO 2016 oral abstract presentation took place on Sunday June 5, 9:45am–12:45pm, during the ‘Hematologic Malignancies-Lymphoma and Chronic Lymphocytic Leukemia’ session. This session was chaired by Pr Gilles Salles, Head of the Hematology Department in South Lyon hospitals, Lyon, France.
Dr Caroline Dartigeas, affiliated to the Hematology Unit of CHU Bretonneau, Tours, France, presented the abstract (#7505).
The CLL 2007 SA trial is a randomized, phase III study conducted by the French FILO group and compares rituximab (RTX) maintenance versus observation (OBS) after induction with fludarabine, cyclophosphamide, and rituximab (FCR) for treating newly diagnosed, fit, elderly (≥65 years) patients with previously untreated Chronic Lymphocytic Leukemia (CLL).
The primary outcome measure for this study was three-year Progression Free Survival (PFS) supplemented by secondary outcome measures which included EFS, OS, and ORR. Inclusion criteria included B-CLL, Matutes score 4 or 5, Binet score B or C, and age ≥65 years, and no del(17p).
Patients were administerd 4 cycles of induction FCR and then 409 patients in CR/PR were randomized to either maintenance rituximab 500mg/m2 q2m for 2 years (n=202), or observation (n=207). At randomization, patients were stratified for IGHV status, del(11q), and response.
In elderly patients with CLL who achieved a response to induction with FCR, PFS was significantly improved with 2 years of maintenance rituximab compared to observation. This benefit was also observed regardless of MRD status, and in patients with unfavorable characteristics such as del(11q) and unmutated IGHV. Moreover, no difference in OS was found between observation and maintenance rituximab. However, a higher incidence of adverse events was found with rituximab maintenance compared to observation, in particular hematologic and infectious events. Caroline Dartigeas concluded the talk by advising that patients should be carefully followed to detect secondary cancers as early as possible and elderly patients should be monitored for long-term toxicities.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox